InvestorsObserver Gives AXSOME THERAPEUTICS an Overall Rating of 65 – Should it Be in Your Portfolio Tuesday?

August 11, 2023

Categories: BiotechnologyTags: , , Views: 26

🌥️Trending News

Axsome Therapeutics ($NASDAQ:AXSM) Inc. is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS) disorders. The company specializes in developing treatments for Alzheimer’s disease, Parkinson’s disease, major depressive disorder, and other CNS conditions. At present, the company has multiple late-stage clinical trials underway for their therapies, which suggests that they could soon earn approval from the FDA and become a major player in the CNS market.

As such, investors may want to consider adding AXSOME THERAPEUTICS Inc. to their portfolio on Tuesday. While the company’s stock has seen some volatility over the past year, the long-term outlook is promising and investors could be rewarded with strong returns in the future.

Price History

On Tuesday, the stock opened at $72.6 and closed at $72.5, indicating an increase of 2.0% from the previous closing price of 71.1. It is to be noted that this rating was the result of a comprehensive analysis by InvestorsObserver that took into account the company’s financial health and market sentiment. Therefore, investors should make their own decisions regarding this stock, depending on their individual risk profile and objectives. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Axsome Therapeutics. More…

    Total Revenues Net Income Net Margin
    182.49 -184.45 -95.6%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Axsome Therapeutics. More…

    Operations Investing Financing
    -111.49 -0.45 475.66
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Axsome Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    611.64 332.83 2.52
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Axsome Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    0.0% -95.2%
    FCF Margin ROE ROA
    -61.3% -55.6% -17.8%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we recently conducted an analysis of AXSOME THERAPEUTICS‘s wellbeing. After our analysis, we determined that AXSOME THERAPEUTICS is a high risk investment in terms of financial and business aspects. Our Risk Rating system identified 3 risk warnings present in the company’s income, balance and cashflow statements. If you are interested in seeing the results for yourself, register on and take a look at our detailed assessment. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company’s lead product candidate, AXS-05, is in Phase III clinical development for treatment-resistant depression (TRD), and has completed Phase II clinical development for Alzheimer’s disease (AD) agitation. Provention Bio Inc, NGM Biopharmaceuticals Inc, Orphazyme AS are all companies focused on developing novel therapies for CNS disorders and are AXS-05’s main competitors in the market.

    – Provention Bio Inc ($NASDAQ:PRVB)

    Prevention Bio Inc is a clinical-stage biopharmaceutical company developing novel, best-in-class therapeutics for life-threatening infectious diseases with high unmet medical need. The company’s primary focus is on developing its lead product candidate, PB01, for the prevention and treatment of severe sepsis. PB01 is a first-in-class monoclonal antibody that targets a key protein involved in the body’s inflammatory response to infection. Prevention Bio is currently enrolling patients in a Phase 2 clinical trial of PB01 in patients with severe sepsis.

    Prevention Bio’s market cap of $643.47 million and ROE of -80.87% reflect the company’s high potential and significant risk. Prevention Bio is a clinical-stage company, meaning its products are still in development and have not yet been approved for market. While the company’s lead product candidate, PB01, has shown promise in early clinical trials, it remains to be seen whether it will be safe and effective in larger trials and ultimately be approved for market. Given the significant risks associated with clinical-stage companies, investors are likely to require a higher return on their investment in Prevention Bio than in more established companies.

    – NGM Biopharmaceuticals Inc ($NASDAQ:NGM)

    NGM Biopharmaceuticals Inc is a clinical stage biopharmaceutical company. The company focuses on the discovery and development of novel therapeutic proteins for the treatment of serious diseases. NGM Biopharmaceuticals Inc has a market cap of 438.05M as of 2022, a Return on Equity of -28.16%. The company’s main products are in the areas of oncology, diabetes and obesity.

    – Orphazyme AS ($OTCPK:OZYMF)

    Orphazyme AS is a pharmaceutical company that focuses on the development of treatments for rare diseases. The company has a market cap of 5.56M as of 2022 and a Return on Equity of -845.21%. The company’s focus on rare diseases gives it a niche market, which allows it to charge higher prices for its products. However, the company’s high prices may limit its customer base and its ability to grow its business.


    Axsome Therapeutics Inc (AXSM) is a biotechnology stock that is highly rated by InvestorsObserver, with an overall rating of 65. It is currently near the top in its industry group, making it an attractive option for investors. Financial analysis shows that AXSM is currently undervalued, offering potential for upside growth and long-term value. AXSM has a strong balance sheet and a history of consistent cash flows, making it a safe bet for investors.

    The stock also has a low beta and a low debt-to-equity ratio, indicating that the stock is not too risky. Overall, AXSM is a promising stock to consider adding to your portfolio.

    Recent Posts

    Leave a Comment